Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...
Illustrative photo Boehringer Ingelheim Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast ...
Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
The following is a summary of “Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: ...
"We are thrilled to welcome Dr. Kokoszynska to our team," said Patrick A. Taylor, York Hospital president and CEO. "Her ...
YORK, Maine – York Hospital announced that Marta Kokoszynska, MD, has joined the medical staff as Medical Director of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback